vs
Side-by-side financial comparison of BioLineRx Ltd. (BLRX) and Core AI Holdings, Inc. (CHAI). Click either name above to swap in a different company.
BioLineRx Ltd. is the larger business by last-quarter revenue ($5.4M vs $3.7M, roughly 1.5× Core AI Holdings, Inc.). BioLineRx Ltd. runs the higher net margin — 9.0% vs -145.7%, a 154.7% gap on every dollar of revenue.
BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
Inflection AI, Inc. is an American technology company which has developed machine learning and generative artificial intelligence hardware and apps, founded in 2022. The company is structured as a public benefit corporation and is headquartered in Palo Alto, California.
BLRX vs CHAI — Head-to-Head
Income Statement — Q2 FY2024 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.4M | $3.7M |
| Net Profit | $484.0K | $-5.4M |
| Gross Margin | 83.4% | 20.1% |
| Operating Margin | -107.0% | -135.2% |
| Net Margin | 9.0% | -145.7% |
| Revenue YoY | — | — |
| Net Profit YoY | 102.6% | — |
| EPS (diluted) | $0.00 | $-1.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $3.7M | ||
| Q2 24 | $5.4M | — | ||
| Q3 23 | — | $1.8M | ||
| Q2 23 | $0 | $2.7M | ||
| Q1 23 | — | $1.8M | ||
| Q3 22 | — | $2.6M | ||
| Q2 22 | — | $969.5K |
| Q3 25 | — | $-5.4M | ||
| Q2 24 | $484.0K | — | ||
| Q3 23 | — | $-1.9M | ||
| Q2 23 | $-18.5M | $-2.3M | ||
| Q1 23 | — | $-4.9M | ||
| Q3 22 | — | $-527.9K | ||
| Q2 22 | — | $-4.3M |
| Q3 25 | — | 20.1% | ||
| Q2 24 | 83.4% | — | ||
| Q3 23 | — | 26.6% | ||
| Q2 23 | — | 29.7% | ||
| Q1 23 | — | 27.5% | ||
| Q3 22 | — | 33.3% | ||
| Q2 22 | — | 11.2% |
| Q3 25 | — | -135.2% | ||
| Q2 24 | -107.0% | — | ||
| Q3 23 | — | -120.8% | ||
| Q2 23 | — | -99.3% | ||
| Q1 23 | — | -147.9% | ||
| Q3 22 | — | -96.2% | ||
| Q2 22 | — | -496.9% |
| Q3 25 | — | -145.7% | ||
| Q2 24 | 9.0% | — | ||
| Q3 23 | — | -100.7% | ||
| Q2 23 | — | -86.1% | ||
| Q1 23 | — | -270.6% | ||
| Q3 22 | — | -20.6% | ||
| Q2 22 | — | -443.9% |
| Q3 25 | — | $-1.74 | ||
| Q2 24 | $0.00 | — | ||
| Q3 23 | — | $-1.04 | ||
| Q2 23 | $-0.02 | — | ||
| Q1 23 | — | $-0.08 | ||
| Q3 22 | — | $-3.19 | ||
| Q2 22 | — | $-0.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $9.6M | $3.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $13.9M | $15.4M |
| Total Assets | $64.6M | $20.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $3.5M | ||
| Q2 24 | $9.6M | — | ||
| Q3 23 | — | $366.2K | ||
| Q2 23 | $10.1M | — | ||
| Q1 23 | — | $1.2M | ||
| Q3 22 | — | $988.6K | ||
| Q2 22 | — | — |
| Q3 25 | — | $15.4M | ||
| Q2 24 | $13.9M | — | ||
| Q3 23 | — | $12.3M | ||
| Q2 23 | $21.1M | $12.0M | ||
| Q1 23 | — | $12.3M | ||
| Q3 22 | — | $11.8M | ||
| Q2 22 | — | $10.4M |
| Q3 25 | — | $20.2M | ||
| Q2 24 | $64.6M | — | ||
| Q3 23 | — | $16.2M | ||
| Q2 23 | $58.9M | $16.6M | ||
| Q1 23 | — | $15.8M | ||
| Q3 22 | — | — | ||
| Q2 22 | — | $18.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | — |
| Free Cash FlowOCF − Capex | $-25.5M | — |
| FCF MarginFCF / Revenue | -472.8% | — |
| Capex IntensityCapex / Revenue | 1.1% | — |
| Cash ConversionOCF / Net Profit | -52.56× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q2 24 | $-25.4M | — | ||
| Q3 23 | — | $-2.7M | ||
| Q2 23 | $-17.7M | $-1.1M | ||
| Q1 23 | — | $-3.1M | ||
| Q3 22 | — | $-2.1M | ||
| Q2 22 | — | — |
| Q3 25 | — | — | ||
| Q2 24 | $-25.5M | — | ||
| Q3 23 | — | — | ||
| Q2 23 | $-17.8M | — | ||
| Q1 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
| Q3 25 | — | — | ||
| Q2 24 | -472.8% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
| Q3 25 | — | — | ||
| Q2 24 | 1.1% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
| Q3 25 | — | — | ||
| Q2 24 | -52.56× | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
